Peel Hunt reaffirmed their add rating on shares of Huntsworth (LON:HNT) in a research report sent to investors on Monday, ThisIsMoney.Co.Uk reports.
A number of other brokerages have also issued reports on HNT. Berenberg Bank reaffirmed a buy rating on shares of Huntsworth in a research report on Thursday, October 10th. Liberum Capital cut their target price on Huntsworth from GBX 120 ($1.58) to GBX 110 ($1.45) and set a buy rating on the stock in a research report on Monday, January 13th. Finally, Peel Hunt reaffirmed a buy rating and set a GBX 135 ($1.78) target price on shares of Huntsworth in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Huntsworth currently has an average rating of Buy and an average target price of GBX 131 ($1.72).
Shares of Huntsworth stock opened at GBX 70 ($0.92) on Monday. The stock’s fifty day moving average is GBX 76.96 and its 200-day moving average is GBX 87.63. The firm has a market capitalization of $259.07 million and a PE ratio of 21.88. The company has a quick ratio of 1.10, a current ratio of 1.19 and a debt-to-equity ratio of 73.94. Huntsworth has a 12-month low of GBX 58.24 ($0.77) and a 12-month high of GBX 112 ($1.47).
Huntsworth plc, together with its subsidiaries, operates as a healthcare and communications company in the United Kingdom and rest of Europe, the United States, and internationally. The company operates through four divisions: Medical, Marketing, Immersive, and Communications. The Medical division provides scientific strategy and communications, publications planning and delivery, specialized medical writing, medical education, and payer and value communications services, as well as support services for internal medical teams.
Recommended Story: Mutual Funds
Receive News & Ratings for Huntsworth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Huntsworth and related companies with MarketBeat.com's FREE daily email newsletter.